Fundraising Fox
Aeglea Biotherapeutics
NASDAQ: SYREacquired by Spyre TherapeuticsAustin, US · Founded 2015 · Delaware corporation · 10 employees on LinkedIn · 2 known investors
Find your way into Aeglea Biotherapeutics
Sign up to see every warm intro you have to Aeglea Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aeglea Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Spyre Therapeutics November 2023 · terms undisclosed — $210M concurrent financing (reverse merger, no traditional purchase price disclosed) · source ↗
Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.
Founders & leadership
Aeglea Biotherapeutics was founded in 2015 by David G. Lowe and George Georgiou.
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$434M disclosed across 3 rounds · 2015–2023
▶$180MraisedDec 2023 · 30 investors · BiotechnologyRule 506(b)
- Cameron TurtleExecutive Officer, Director
- Tomas KiselakDirector
- Scott BurrowsExecutive Officer
- Laurie StelzerDirector
- Russell J. CoxDirector
- Peter HarwinDirector
- Alison LawtonDirector
- Michael HendersonDirector
- Heidy King-JonesExecutive Officer
- Jeffrey W. AlbersDirector
- Offering amount
- $180M
- Amount sold
- $180M
- Finders' fees
- $10.8M
- Placement agents
- Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated, Guggenheim Securities, LLC, LifeSci Capital LLC, Jefferies LLC
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$210MraisedJul 2023 · 41 investors · BiotechnologyRule 506(b)
- Tomas KiselakDirector
- Peter HarwinDirector
- Michael HendersonDirector
- Cameron TurtleExecutive Officer
- Jonathan AlspaughExecutive Officer
- Alison LawtonDirector
- Ivana Magovcevic-LiebischDirector
- Hunter C, SmithDirector
- Russell J. CoxDirector
- Cortney CaudillExecutive Officer
- Offering amount
- $210M
- Amount sold
- $210M
- Finders' fees
- $12.6M
- Placement agents
- Cowen and Company, LLC, Guggenheim Securities, LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44MraisedMar 2015 · 54 investors · BiotechnologyRule 506(b)
- Charles N. YorkExecutive Officer
- David G. LoweExecutive Officer, Director
- Henry SkinnerDirector
- George GeorgiouDirector
- Armen ShanafeltDirector
- Offering amount
- $44M
- Amount sold
- $44M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Aeglea Biotherapeutics do?
- Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.
- Who founded Aeglea Biotherapeutics?
- Aeglea Biotherapeutics was founded by David G. Lowe, George Georgiou in 2015.
- Who are Aeglea Biotherapeutics's investors?
- Aeglea Biotherapeutics's investors include Aisling Capital, RA Capital.
- How much funding has Aeglea Biotherapeutics raised?
- Aeglea Biotherapeutics has disclosed $434M raised across 3 rounds.
- Who acquired Aeglea Biotherapeutics?
- Aeglea Biotherapeutics was acquired by Spyre Therapeutics.
- Where is Aeglea Biotherapeutics headquartered?
- Aeglea Biotherapeutics is headquartered in Austin, US.